{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T02:15:34Z","timestamp":1777515334990,"version":"3.51.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T00:00:00Z","timestamp":1588204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T00:00:00Z","timestamp":1588204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In ASTRAEA (NCT01860976), abatacept significantly increased American College of Rheumatology criteria 20% (ACR20) responses at Week 24 versus placebo in patients with psoriatic arthritis (PsA). This post hoc analysis explored relationships between prospectively identified baseline characteristics [poor prognostic factors (PPFs) ] and response to abatacept. Patients were randomized (1:1) to receive subcutaneous abatacept 125\u00a0mg weekly or placebo for 24\u00a0weeks; those without\u2009\u2265\u200920% improvement in joint counts at Week 16 switched to open-label abatacept. Potential predictors of ACR20 response were identified by treatment arm using multivariate analyses. Likelihood of ACR20 response to abatacept versus placebo was compared in univariate and multivariate analyses in subgroups stratified by the PPF, as defined by EULAR and\/or GRAPPA treatment guidelines. Odds ratios (ORs) were generated using logistic regression to identify meaningful differences (OR cut-off: 1.2). 424 patients were randomized and treated (abatacept<jats:italic>n<\/jats:italic>\u2009=\u2009213; placebo<jats:italic>n<\/jats:italic>\u2009=\u2009211). In abatacept-treated patients, elevated C-reactive protein (CRP), high Disease Activity Score based on 28 joints (CRP), presence of dactylitis, and\u2009\u2265\u20093 joint erosions were identified as predictors of response (OR\u2009&gt;\u20091.2). In placebo-treated patients, only dactylitis was a potential predictor of response. In the univariate analysis stratified by PPF, ACR20 response was more likely (OR\u2009&gt;\u20091.2) with abatacept versus placebo in patients with baseline PPFs than in those without; multivariate analysis confirmed this finding. Response to abatacept versus placebo is more likely in patients with features indicative of high disease activity and progressive disease; these characteristics are recognized as PPFs in treatment guidelines for PsA.<\/jats:p>","DOI":"10.1007\/s00296-020-04564-x","type":"journal-article","created":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T12:02:42Z","timestamp":1588248162000},"page":"1021-1028","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritis"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J.","family":"Mease","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iain B.","family":"McInnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vibeke","family":"Strand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"FitzGerald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harris A.","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yedid","family":"Elbez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subhashis","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,30]]},"reference":[{"issue":"Suppl 2","key":"4564_CR1","first-page":"ii14","volume":"64","author":"DD Gladman","year":"2005","unstructured":"Gladman DD, Antoni C, Mease P, Clegg DO, Nash P (2005) Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 64(Suppl 2):ii14\u2013ii17","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"4564_CR2","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/ar2580","volume":"11","author":"O FitzGerald","year":"2009","unstructured":"FitzGerald O, Winchester R (2009) Psoriatic arthritis: from pathogenesis to therapy. Arthritis Res Ther 11(1):214","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"4564_CR3","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1136\/annrheumdis-2015-208466","volume":"75","author":"S Ramiro","year":"2016","unstructured":"Ramiro S, Smolen JS, Landewe R, van der Heijde D, Dougados M, Emery P et al (2016) Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 75(3):490\u2013498","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"4564_CR4","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.autrev.2013.01.001","volume":"12","author":"M Cutolo","year":"2013","unstructured":"Cutolo M, Nadler S (2013) Advances in CTLA-4-Ig-mediated modulation of inflammatory cell and immune response activation in rheumatoid arthritis. Autoimmun Rev 12(7):758\u2013767","journal-title":"Autoimmun Rev"},{"key":"4564_CR5","unstructured":"Orencia prescribing information. 2017. https:\/\/packageinserts.bms.com\/pi\/pi_orencia.pdf. Accessed 2 Feb 2018."},{"key":"4564_CR6","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1136\/annrheumdis-2016-210724","volume":"76","author":"PJ Mease","year":"2017","unstructured":"Mease PJ, Gottlieb AB, van der Heijde D, FitzGerald O, Johnsen A, Nys M et al (2017) Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. Ann Rheum Dis 76:1550\u20131558","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"4564_CR7","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","volume":"75","author":"L Gossec","year":"2016","unstructured":"Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M et al (2016) European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 75(3):499\u2013510","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"4564_CR8","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","volume":"68","author":"LC Coates","year":"2016","unstructured":"Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Laura Acosta-Felquer M, Armstrong AW et al (2016) Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol 68(5):1060\u20131071","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"4564_CR9","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/acr.23789","volume":"71","author":"JA Singh","year":"2019","unstructured":"Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A et al (2019) Special article: 2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Care Res (Hoboken) 71(1):2\u201329","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4564_CR10","unstructured":"Alemao E, Postema R, Elbez Y, Mamane C, Finckh A (2019) Presence of anti-cyclic citrullinated peptide antibodies is associated with better treatment response to abatacept but not to TNF inhibitors in patients with rheumatoid arthritis: a meta-analysis. Clin Exp Rheumatol"},{"issue":"1","key":"4564_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/03009742.2019.1627411","volume":"49","author":"Y Endo","year":"2020","unstructured":"Endo Y, Koga T, Kawashiri SY, Morimoto S, Nishino A, Okamoto M et al (2020) Anti-citrullinated protein antibody titre as a predictor of abatacept treatment persistence in patients with rheumatoid arthritis: a prospective cohort study in Japan. Scand J Rheumatol 49(1):13\u201317","journal-title":"Scand J Rheumatol"},{"issue":"4","key":"4564_CR12","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1136\/annrheumdis-2015-207942","volume":"75","author":"J Sokolove","year":"2016","unstructured":"Sokolove J, Schiff M, Fleischmann R, Weinblatt ME, Connolly SE, Johnsen A et al (2016) Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial. Ann Rheum Dis 75(4):709\u2013714","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"4564_CR13","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54(8):2665\u20132673","journal-title":"Arthritis Rheum"},{"issue":"6","key":"4564_CR14","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landew\u00e9 R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M et al (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76(6):960\u2013977","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"4564_CR15","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1136\/ard.2008.090019","volume":"68","author":"JS Smolen","year":"2009","unstructured":"Smolen JS, Han C, van der Heijde DM, Emery P, Bathon JM, Keystone E et al (2009) Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis 68(6):823\u2013827","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"4564_CR16","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1136\/ard.2008.101121","volume":"68","author":"R Westhovens","year":"2009","unstructured":"Westhovens R, Robles M, Ximenes AC, Nayiager S, Wollenhaupt J, Durez P et al (2009) Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 68(12):1870\u20131877","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"4564_CR17","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1136\/ard.2010.145268","volume":"70","author":"J Bathon","year":"2011","unstructured":"Bathon J, Robles M, Ximenes AC, Nayiager S, Wollenhaupt J, Durez P et al (2011) Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes. Ann Rheum Dis 70(11):1949\u20131956","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"4564_CR18","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1136\/ard.2003.018184","volume":"64","author":"JE Brockbank","year":"2005","unstructured":"Brockbank JE, Stein M, Schentag CT, Gladman DD (2005) Dactylitis in psoriatic arthritis: a marker for disease severity? Ann Rheum Dis 64(2):188\u2013190","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4564_CR19","first-page":"45","volume":"30","author":"P Simon","year":"2012","unstructured":"Simon P, Pfoehler C, Bergner R, Schreiber M, Pfreundschuh M, Assmann G (2012) Swollen joint count in psoriatic arthritis is associated with progressive radiological damage in hands and feet. Clin Exp Rheumatol 30(1):45\u201350","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"4564_CR20","doi-asserted-by":"publisher","first-page":"R113","DOI":"10.1186\/ar3049","volume":"12","author":"DD Gladman","year":"2010","unstructured":"Gladman DD, Mease PJ, Choy EH, Ritchlin CT, Perdok RJ, Sasso EH (2010) Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT. Arthritis Res Ther 12(3):R113","journal-title":"Arthritis Res Ther"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-020-04564-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-020-04564-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-020-04564-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T13:53:38Z","timestamp":1696082018000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-020-04564-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,30]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["4564"],"URL":"https:\/\/doi.org\/10.1007\/s00296-020-04564-x","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,30]]},"assertion":[{"value":"8 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"PJM reports receiving grant support from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Lilly, Novartis, Pfizer, Sun, and UCB; consulting fees from AbbVie, Amgen, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Sun, and UCB; and speaker fees from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Genentech, Janssen, Lilly, Novartis, Pfizer, and UCB. IBM reports receiving research grants from Bristol-Myers Squibb, Celgene, Janssen, Novartis, and UCB; and consulting fees from AbbVie, Bristol-Myers Squibb, Celgene, Janssen, Novartis, and UCB. VS reports receiving consulting fees from AbbVie, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Celltrion, Corrona, Crescendo, Genentech\/Roche, GlaxoSmithKline, Janssen, Lilly, Merck, Novartis, Pfizer, Regeneron, Samsung, Sandoz, Sanofi, and UCB. OF reports receiving research grants from Bristol-Myers Squibb. HAA and SB are employees of Bristol-Myers Squibb and report holding stock in Bristol-Myers Squibb. YE is consultant for Bristol-Myers Squibb.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Schulman Associates Institutional Review Board or Independent Ethics Committees approved the protocol, consent form, and any other written information provided to patients or their legal representatives.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"All patients gave written informed consent prior to study entry.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}}]}}